Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23

被引：419

作者：

Degirolamo, Chiara ^{[1
,2
]}

Sabba, Carlo ^{[1
]}

Moschetta, Antonio ^{[1
,2
]}

机构：

[1] Univ Bari Aldo Moro, Clin Med Cesare Frugoni, Dipartimento Interdisciplinare Med, I-70124 Bari, Italy

[2] IRCCS, Ist Tumori Giovanni Paolo 2, I-70124 Bari, Italy

来源：

NATURE REVIEWS DRUG DISCOVERY | 2016年 / 15卷 / 01期

关键词：

BILE-ACID SYNTHESIS; FARNESOID-X-RECEPTOR; INCREASES ENERGY-EXPENDITURE; LEFT-VENTRICULAR HYPERTROPHY; ORPHAN NUCLEAR RECEPTOR; PPAR-ALPHA ACTIVATION; FACTOR; 21; EXPRESSION; INDUCED OBESE MICE; VITAMIN-D; BETA-KLOTHO;

D O I：

10.1038/nrd.2015.9

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 [微生物学]; 090105 [作物生产系统与生态工程];

摘要：

The endocrine fibroblast growth factors (FGFs), FGF19, FGF21 and FGF23, are critical for maintaining whole-body homeostasis, with roles in bile acid, glucose and lipid metabolism, modulation of vitamin D and phosphate homeostasis and metabolic adaptation during fasting. Given these functions, the endocrine FGFs have therapeutic potential in a wide array of chronic human diseases, including obesity, type 2 diabetes, cancer, and kidney and cardiovascular disease. However, the safety and feasibility of chronic endocrine FGF administration has been challenged, and FGF analogues and mimetics are now being investigated. Here, we discuss current knowledge of the complex biology of the endocrine FGFs and assess how this may be harnessed therapeutically.

引用

收藏

页码：51 / 69

页数：19

相关论文

共 238 条

[1]

Fibroblast growth factor 21 is not required for the antidiabetic actions of the thiazoladinediones [J].

Adams, Andrew C. ;

Coskun, Tamer ;

Cheng, Christine C. ;

O'Farrell, Libbey S. ;

DuBois, Susan L. ;

Kharitonenkov, Alexei .

MOLECULAR METABOLISM, 2013, 2 (03) :205-214

[2]

The breadth of FGF21's metabolic actions are governed by FGFR1 in adipose tissue [J].

Adams, Andrew C. ;

Yang, Chaofeng ;

Coskun, Tamer ;

Cheng, Christine C. ;

Gimeno, Ruth E. ;

Luo, Yongde ;

Kharitonenkov, Alexei .

MOLECULAR METABOLISM, 2013, 2 (01) :31-37

[3]

LY2405319, an Engineered FGF21 Variant, Improves the Metabolic Status of Diabetic Monkeys [J].

Adams, Andrew C. ;

Halstead, Carolyn A. ;

Hansen, Barbara C. ;

Irizarry, Armando R. ;

Martin, Jennifer A. ;

Myers, Sharon R. ;

Reynolds, Vincent L. ;

Smith, Holly W. ;

Wroblewski, Victor J. ;

Kharitonenkov, Alexei .

PLOS ONE, 2013, 8 (06)

[4]

FGF21 Requires βklotho to Act In Vivo [J].

Adams, Andrew C. ;

Cheng, Christine C. ;

Coskun, Tamer ;

Kharitonenkov, Alexei .

PLOS ONE, 2012, 7 (11)

[5]

Thyroid Hormone Regulates Hepatic Expression of Fibroblast Growth Factor 21 in a PPARα-dependent Manner [J].

Adams, Andrew C. ;

Astapova, Inna ;

Fisher, Ffolliott M. ;

Badman, Michael K. ;

Kurgansky, Katherine E. ;

Flier, Jeffrey S. ;

Hollenberg, Anthony N. ;

Maratos-Flier, Eleftheria .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2010, 285 (19) :14078-14082

[6]

PPARγ signaling and metabolism: the good, the bad and the future [J].

Ahmadian, Maryam ;

Suh, Jae Myoung ;

Hah, Nasun ;

Liddle, Christopher ;

Atkins, Annette R. ;

Downes, Michael ;

Evans, Ronald M. .

NATURE MEDICINE, 2013, 19 (05) :557-566

[7]

Plasma FGF21 displays a circadian rhythm during a 72-h fast in healthy female volunteers [J].

Andersen, Birgitte ;

Beck-Nielsen, Henning ;

Hojlund, Kurt .

CLINICAL ENDOCRINOLOGY, 2011, 75 (04) :514-519

[8]

FGF23 acts directly on renal proximal tubules to induce phosphaturia through activation of the ERK1/2-SGK1 signaling pathway [J].

Andrukhova, Olena ;

Zeitz, Ute ;

Goetz, Regina ;

Mohammadi, Moosa ;

Lanske, Beate ;

Erben, Reinhold G. .

BONE, 2012, 51 (03) :621-628

[9]

Aono Y, 2009, J BONE MINER RES, V24, P1879, DOI [10.1359/JBMR.090509, 10.1359/jbmr.090509]

[10]

Badman MK, 2007, CELL METAB, V5, P426, DOI 10.1016/j.cmet.2007.05.002

← 1 2 3 4 5 6 7 8 9 10 →